Loading...
NPI 1952692410 · Ellensburg, WA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Cindy Mi is a ophthalmology physician provider located in Ellensburg, Washington. This profile covers 19 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Cindy Mi |
| Address | 2205 W Dolarway Rd Ste 2 |
| City | Ellensburg |
| State | WA |
| ZIP | 98926 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | May 2, 2011 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.4M |
| Medicaid | $170 |
This clinician is an ophthalmology physician in Ellensburg, WA with an NPI enumerated on 2011-05-02 (~15 years ago), indicating long-standing Medicare/Medicaid participation and likely an established outpatient practice footprint in the region. Tenure suggests sustained billing activity and experience managing ophthalmic services over a multiyear period.
Medicare revenue dominates this provider’s payer mix: total Medicare revenue is $1.4M versus total Medicaid revenue of $168, indicating the practice is effectively single-payer in commercial scale and relies almost entirely on Medicare for material reimbursement streams. Medicaid activity is negligible relative to Medicare and does not meaningfully contribute to overall revenues.
Revenue concentration on Medicare is high and focused in anti-VEGF and related retinal procedures: the top 3 Medicare codes account for 79.8% of total Medicare revenue, driven by J0178 ($628.4K, 44.6%), J2777 ($327.1K, 23.2%), and Q5128 ($168.3K, 11.9%). This mix indicates a service-line orientation toward intravitreal injections and biologic therapy for retinal disease as the core revenue-driving activity.
Beyond drug administration, procedure codes supporting retinal imaging and injection procedures also appear: 67028 ($88.4K, 6.3%) and 92134 ($48.9K, 3.5%) are present, reinforcing that the practice couples medication administration with diagnostic retinal imaging and office-based injection services rather than high volumes of broad-scope comprehensive eye exams. Office E/M codes (99213, 99214, 92014) are present but account for small shares, consistent with a treatment-focused retinal practice rather than a general ophthalmology primary care model.
Competitive standing on Medicare is mixed by code: for the largest revenue driver J0178 the provider ranks #1371 of 3204 (57th percentile), for J2777 ranks #919 of 2039 (55th percentile), and for Q5128 ranks #167 of 373 (55th percentile) — these percentiles indicate typical, unremarkable national volume for those anti-VEGF/biosimilar injections and place this provider as a modest, not dominant, participant in these drug administration markets. In contrast, the provider’s 92134 volume ranks #1390 of 26868 (95th percentile), which is characterized as notably above typical national volume and suggests an above-average emphasis on retinal imaging compared with peers.
Medicaid billing is effectively immaterial and highly concentrated: total Medicaid revenue of $168 is entirely comprised of 92134 (213 claims, $213 revenue, 100.0% of Medicaid revenue), with the next Medicaid code 67028 showing claims but $0 revenue recorded. The provider ranks #54 of 100 in-state for 92134 (46th percentile), indicating in-state Medicaid volume for this retinal imaging code is around the middle of peers and not a distinguishing competitive advantage.
Procedure-level volume/price signals show this practice bills large counts of injection claims for certain drugs but at industry-typical placement: J0178 shows 916 claims at $686 avg paid/claim and J2777 shows 11.3K claims at $29 avg paid/claim, reflecting high utilization of injectable therapeutics as a core operational activity. Those claim counts combined with the heavy Medicare revenue concentration on three codes support a business model centered on frequent, office-based intravitreal treatments with ancillary imaging and occasional intraocular surgery (e.g., 67042 present at lower volume).
Service mix and revenue profile imply operational priorities: high reliance on injectable biologics and retinal imaging suggests investment in injection suite workflow, stock/handling of ophthalmic biologics, and diagnostic imaging capability (OCT/retinal cameras). Given the modest ranking on national drug-administration benchmarks but unusually high retinal imaging percentile, the practice may differentiate locally through diagnostic throughput rather than by volume leadership in drug administration.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 920 | $690 | $628.4K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 11,280 | $30 | $327.1K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 780 | $220 | $168.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 940 | $90 | $88.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,630 | $30 | $48.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 320 | $90 | $29.1K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 440 | $70 | $28.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 250 | $90 | $22.2K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 20 | $950 | $19.1K |
| J7999 | Compounded drug, not otherwise classified | 190 | $70 | $13.6K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
19 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2777 | 27 | 50 | 12,780 | $30 | $599.7K |
| J0178 | 35 | 90 | 470 | $680 | $597.2K |
| Q5128 | 4 | 10 | 520 | $220 | $136.6K |
| 67028 | 41 | 110 | 550 | $90 | $72.9K |
| 67042 | 22 | 40 | 30 | $1,190 | $39.2K |
| 92014 | 157 | 790 | 110 | $80 | $16.8K |
| J7999 | 29 | 70 | 150 | $70 | $15.9K |
| 99214 | 2,097 | 10,860 | 100 | $80 | $13.6K |
| J9035 | 36 | 40 | 70 | $50 | $10.9K |
| 92235 | 52 | 50 | 50 | $110 | $8.3K |
Showing 1–10 of 19
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 210 | $1 | $210 |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 100 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 43 | 60 | 710 | $40 | $81.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 54 | 100 | 240 | $10 | $22.2K |
Other providers in the same ZIP code as Cindy Mi, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Kittitas County Public Hospital Dist 1 | WA | Critical Access Hospital | $0 | $39.1M |
| Kittitas County Public Hospital Dist 1 | WA | Rural Health Clinic/Center | $0 | $19.5M |
| Kittitas Valley Urgent Care PLLC | WA | Urgent Care Clinic/Center | $0 | $7M |
| Kittitas County Fire Protection District 2 | WA | Land Ambulance | $579.6K | $4.3M |
| Daniel Hanson | WA | Ophthalmology Physician | $454.6K | $0 |
| Erick Johnson | WA | Optometrist | $114.1K | $510 |
| Casey Oltman | WA | Optometrist | $96.8K | $0 |
| Jamin Feng | WA | Internal Medicine Physician | $42.5K | $0 |
| Roberta Hoppe | WA | Clinical Cardiac Electrophysiology Physician | $27.8K | $0 |
| Kenneth Gano | WA | Certified Registered Nurse Anesthetist | $17K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.